Multiple myeloma therapeutics industry is projected to witness a CAGR of 6.4% during the period 2024-2032. This growth can be ...

"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...

More than 200 people were reported rescued from floodwaters in North Carolina following Helene’s torrential rains with more ...

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

Radiotherapy had a distinct advantage over surgery in reducing myeloma progression while maintaining comparable survival ...

The Maple Ridge resident was surprised considering, as he has since learned, multiple myeloma is the second most prevalent ...